LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Ocular Therapeutix Inc

Geschlossen

BrancheGesundheitswesen

12.68 4.53

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

12.12

Max

12.75

Schlüsselkennzahlen

By Trading Economics

Einkommen

-3.8M

-68M

Verkäufe

2.8M

13M

Gewinnspanne

-503.856

Angestellte

274

EBITDA

146K

-64M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+46.22% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

13. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

262M

2.2B

Vorheriger Eröffnungskurs

8.15

Vorheriger Schlusskurs

12.68

Nachrichtenstimmung

By Acuity

61%

39%

330 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Ocular Therapeutix Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Sept. 2025, 23:56 UTC

Heiße Aktien

Stocks to Watch: FedEx, 22nd Century, Scholastic

18. Sept. 2025, 22:01 UTC

Wichtige Markttreiber

22nd Century Group Shares Gain on Debt Repayment, New Capital

18. Sept. 2025, 20:51 UTC

Akquisitionen, Fusionen, Übernahmen

UPS Terminates Plan to Buy Estafeta

18. Sept. 2025, 20:31 UTC

Ergebnisse

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

18. Sept. 2025, 20:26 UTC

Ergebnisse

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

18. Sept. 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. Sept. 2025, 23:43 UTC

Market Talk

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

18. Sept. 2025, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

18. Sept. 2025, 23:40 UTC

Market Talk

Gold Edges Lower Amid Cautious Mood -- Market Talk

18. Sept. 2025, 23:31 UTC

Market Talk

FedEx Says U.S. Demand Is Resilient -- Market Talk

18. Sept. 2025, 22:03 UTC

Ergebnisse

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

18. Sept. 2025, 22:01 UTC

Ergebnisse

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

18. Sept. 2025, 21:56 UTC

Ergebnisse

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

18. Sept. 2025, 21:54 UTC

Ergebnisse

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

18. Sept. 2025, 21:48 UTC

Ergebnisse

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

18. Sept. 2025, 21:47 UTC

Ergebnisse

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

18. Sept. 2025, 21:17 UTC

Ergebnisse

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

18. Sept. 2025, 21:07 UTC

Ergebnisse

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18. Sept. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. Sept. 2025, 20:50 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

18. Sept. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

18. Sept. 2025, 20:22 UTC

Akquisitionen, Fusionen, Übernahmen

UPS Cites Inability of All Closing Conditions to Be Satisfied

18. Sept. 2025, 20:22 UTC

Akquisitionen, Fusionen, Übernahmen

United Parcel Service Terminates Plan to Buy Estafeta

18. Sept. 2025, 20:20 UTC

Akquisitionen, Fusionen, Übernahmen

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

18. Sept. 2025, 20:18 UTC

Ergebnisse

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

18. Sept. 2025, 20:18 UTC

Ergebnisse

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

18. Sept. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. Sept. 2025, 20:07 UTC

Ergebnisse

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18. Sept. 2025, 20:03 UTC

Ergebnisse

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Peer-Vergleich

Kursveränderung

Ocular Therapeutix Inc Prognose

Kursziel

By TipRanks

46.22% Vorteil

12-Monats-Prognose

Durchschnitt 17.78 USD  46.22%

Hoch 21 USD

Tief 14 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ocular Therapeutix Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

10

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

6.97 / 7.62Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

330 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
help-icon Live chat